Multiple Myeloma Hub
A podcast by Scientific Education Support
57 Episoade
-
What is the rationale for treating early RRRM with targeted therapies?
Publicat: 02.05.2025 -
What is the impact of belantamab mafodotin on QoL in patients with MM?
Publicat: 30.04.2025 -
What is the impact of elranatamab on quality of life in relapsed/refractory multiple myeloma?
Publicat: 29.04.2025 -
Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma
Publicat: 13.08.2024 -
Integrating cilta-cel into earlier lines of therapy: Rationale and latest data from CARTITUDE-2 and CARTITUDE-4
Publicat: 09.08.2024 -
Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma
Publicat: 09.08.2024 -
Teclistamab: real-world safety and efficacy
Publicat: 08.08.2024 -
Infections associated with bispecific antibodies
Publicat: 16.07.2024 -
CAR T-cell therapies in clinical practice
Publicat: 16.07.2024 -
How to select maintenance therapies post-ASCT for patients with high-risk MM?
Publicat: 18.09.2023 -
Should risk-adapted MM treatment be informed by age or frailty status?
Publicat: 12.09.2023 -
How is the immune reconstitution in patients who stop therapy after achieving MRD negativity?
Publicat: 09.02.2023 -
What are the main discrepancies between MM treating centers in Brazil?
Publicat: 06.02.2023 -
What are the initial data of dara-CyBorD in patients with extramedullary disease?
Publicat: 03.02.2023 -
Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?
Publicat: 02.10.2022 -
Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM
Publicat: 05.08.2022 -
The role of consolidation after autologous stem cell transplantation
Publicat: 05.08.2022 -
What are the pros and cons of bispecific antibodies for multiple myeloma?
Publicat: 25.07.2022 -
Combining bispecific antibodies with monoclonal antibodies to treat relapsed/refractory MM
Publicat: 21.04.2022 -
Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?
Publicat: 14.01.2022
Guided by an international Steering Committee of world experts in Multiple Myeloma (MM), the MM Hub is a global online resource providing key information on Multiple Myeloma for hematologists, oncologists and researchers, run in collaboration with the European School of Haematology (ESH). Our mission is to provide the latest global up-to-date clinical guidance in Multiple Myeloma, through a comprehensive coverage of evidence-based literature, drug approvals, case studies, expert opinions and international congress reports. Hosted on Acast. See acast.com/privacy for more information.
